Suven Life gets product patents in South Africa, China

Drug maker Suven Life Sciences Ltd has received product patents in South Africa and China for two of its new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases.

The patents, valid until 2024 and 2025 respectively, will be the exclusive intellectual property of Suven. The drug candidates were discovered through internal research efforts.

Products out of these inventories, which are in pre-clinical development, may be out-licensed at the stage of clinical phase-I or phase-II stage.

''We are pleased by the issuance of these patents in these countries to Suven for our drug candidates that are being developed for CNS disorders which targets an $18 billion potential market opportunity globally,'' said Venkat Jasti, CEO of Suven.
 
The granted patent claims include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents in the treatment of cognitive impairment associated with neurodegenerative disorders like attention deficient hyperactivity, Alzheimer`s, Parkinson, schizophrenia and Huntington's.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products.

The company currently has six internally-discovered therapeutic drug candidates, in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease. Parkinson's disease and obesity are in addition to developmental candidates in Alzheimer's disease and Schizophrenia.